3.93
-0.01 (-0.25%)
| Previous Close | 3.94 |
| Open | 3.95 |
| Volume | 858,622 |
| Avg. Volume (3M) | 650,518 |
| Market Cap | 370,676,416 |
| Price / Sales | 31.78 |
| Price / Book | 2.22 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Profit Margin | 46.54% |
| Operating Margin (TTM) | -32.78% |
| Diluted EPS (TTM) | 2.11 |
| Total Debt/Equity (MRQ) | 340.14% |
| Current Ratio (MRQ) | 3.70 |
| Operating Cash Flow (TTM) | -109.67 M |
| Levered Free Cash Flow (TTM) | -78.01 M |
| Return on Assets (TTM) | -58.61% |
| Return on Equity (TTM) | 121.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | X4 Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 5.0 |
| Average | 1.50 |
|
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.43% |
| % Held by Institutions | 55.70% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |